EPIDEMIOLOGY AND ASSOCIATIONS
The true prevalence of NASH is unknown because of the inherent selection bias in patients scheduled for liver biopsy.
NASH has been reported in 1% to 9% of patients undergoing liver biopsy.
2 A Wanless and Lentz 5 reported the autopsy prevalence of NASH in 22 (6%) of 351 apparently nonalcoholic patients. The prevalence ranged from 2.7% of those who were not overweight to 18.5% of those who were greater than 40% above their ideal body weight. NASH has been described most frequently in obese females who are diabetic or hyperlipidemic (Table 1) ; however, it has also been described in male patients who are non-obese, non-diabetic, and normolipidemic. 10 Bacon et al 10 reported a higher occurrence of NASH in males than previously recognized. NASH also occurs in children.
The single most consistent association with NASH is obesity, with a reported prevalence of 40% to l00%. Most patients with NASH are either overweight (body mass index [BMI] >25 kg/m 2 ) or obese (BMI > 30 kg/m 2 ). A high degree of correlation between severity of hepatic steatosis and fibrosis and total fat mass, as estimated by the BMI, has been reported, 13 and weight loss has been shown to result in biochemical and histological improvement in patients with NASH. 14 Some observers have demonstrated a relationship between fatty liver and the regional body distribution of adipose tissue. Kral et a1 15 showed that the abdominal distribution of fat, which is reflected by an elevated waist-hip ratio, is a predictor of hepatic steatosis, an effect independent of body weight or total body fat. Type 2 diabetes mellitus and glucose intolerance have been reported in 21% to 75% of patients with NASH. 15 -' 0 Hyperlipidemia is also a common association, with a reported prevalence of 21% to 83%. The role of diabetes and hyperlipidemia in the pathogenesis of NASH is still unclear, although the presence of diabetes has been found to correlate with the degree of fibrosis. 50  67  Itoh et al  16  75  100  5  63  Diehl et al   7   39  81  71  55  20  Lees.  49  78  95  51  NR   Powell et al   9   42  83  95  36  81  Bacon et al'   0   33  42  39  21  21  Laurin et al   1   40  73  70  28  NR  Pinto et al   12   32  75  47  34  28 *There is wide variability among these studies regarding definitions used (especially for obesity and diabetes), population sampled, etc, and this greatly limits comparability among studies. NR = not reported.
NASH IN CHILDREN
Neither NASH nor obesity is solely an adult disorder. Baldridge et al 16 reported NASH in 14 of 32 children with hepatic steatosis, all of whom were obese, and 10 had bridging fibrosis. Among 299 obese children, Kinugasa et a1 17 noted that 12% had elevated aminotransferase levels, and NASH was diagnosed in 73% of those who underwent liver biopsy. In a recent series of 36 children with NASH, fibrosis was noted in 71% of those who underwent liver biopsy, and 1 had established cirrhosis at diagnosis; 83% were obese, and 18 of 20 patients studied had hyperlipidemia. 18 Thus, NASH may not be rare in children, especially in obese children, and severe fibrosis may be found at any early age. Therefore, NASH should be considered in obese children with elevated aminotransferase levels.
The elevated serum aminotransferase levels in such children have been demonstrated to decrease or normalize with weight 1055.14, 18 Whether weight loss also results in improvement in liver histology is unknown. The effect maturation has on NASH in children is also unknown. Substantial improvement in aminotransferase levels has been noted with consumption of vitamin E, an antioxidant, in children with NASH.'
9 Long-term follow-up observations on the efficacy of vitamin E are awaited. As in adults, the pathogenesis of NASH in children is still unclear. However, the common epidemiological associations among adult and pediatric patients with NASH suggest similar pathogenic mechanisms.
PATHOLOGY
Liver histology in NASH is characterized by fatty change and hepatocyte injury (inflammation, Mallory hyalin, or necrosis) with or without fibrosis ( Table 2 ). The spectrum of histological changes varies from mild steatohepatitis to bridging fibrosis and cirrhosis. Hepatic steatosis in NASH is macrovesicular and primarily centrilobular (zone 3), although it may be diffuse in severe forms of the disease. Inflammation, which must be present for the diagnosis of NASH, is usually low grade, lobular, and mixed neutrophilic and mononuclear. Of note is the absence of severe portal or periportal inflammation, and the presence of severe portal inflammation suggests an alternative diagnosis. Mallory hyalin, if present, is usually less prominent than that in alcoholic hepatitis. Fibrosis, which is initially perisinusoidal (pericellular), may progress to cirrhosis. The reported prevalence of fibrosis in NASH on the initial biopsy specimen ranges from 15% to 100%, with cirrhosis noted in up to 15% of specimens. 2 . 9 Compared to hepatic histological findings in alcoholic hepatitis, the steatosis in NASH is more often severe, and glycogenation of nuclei is more prominent.
6 ' 7 A difficult problem in interpreting liver histological findings in suspected NASH is variation of the criteria used by pathologists for the diagnosis. 
PATHOGENESIS
The pathogenesis of NASH is poorly defined. The factor responsible for the transition of a liver with excess triglyceride levels (i.e., fatty liver) to one with an ongoing inflammatory process (i.e., NASH) is unclear. The major hypotheses center around the roles of oxidative stress, lipid peroxidation, and cytokine release.
Investigators have proposed that the development of steatohepatitis from simple steatosis requires a second process that tends to overcome the normal cellular defenses by increasing the normal mild level of oxidative stress that is constitutively present. 20 Potential sources of increased oxidative stress include increased expression of the cytochrome P-450 (CYP) 2E1, which generates superoxide, hydroxyl, and hydroxyethyl radicals, and peroxisomal β-oxidation of free fatty acids, which generates hydrogen peroxide. In hepatic steatosis, excess triglyceride levels may be present as substrate for peroxidation. Hepatic lipid peroxidation may lead to formation of cytotoxic intermediates, which may cause cellular injury directly or by initiating an inflammatory response. Free fatty acids, which are thought to be a key initiating factor in NASH pathogenesis, can induce cytochrome P-450 2E1, an outcome resulting in increased generation of reactive oxygen species and lipid peroxidation leading to damage to biological membranes. These hypothesized, important intracellular disturbances may result in propagation of inflammation and cell injury.
Interindividual differences in the severity of NASH might be explained by the magnitude of the oxidative stress or may be determined genetically (such as having a more readily inducible form of CYP 2E1) or by environmental factors such as dietary intake of antioxidants or exposure to pro-oxidant stresses.
In alcohol-induced liver disease, CYP 2E 1 seems to have an important role in the generation of free radicals, resulting in lipid peroxidation and hepatocyte damage. 21 Increased hepatic CYP 2E1 is the first potential pathophysiologic defect to be demonstrated in humans with NASH. 22 Increased CYP 2E1 in NASH has been demonstrated by immunostaining, and the distribution corresponded to that of steatosis, with extension into zones 2 and 1 in severe cases. The increased CYP 2E1 noted was independent of associated obesity, diabetes, or hyperlipidemia. Therefore, there is increasing evidence that CYP 2E1 has an important role in the pathogenesis of NASH in humans.
As in alcoholic steatohepatitis, endotoxins and certain endotoxin-inducible cytokines, such as tumor necrosis factor Q, are also thought to have a role in NASH. 23 This is supported by the fact that patients undergoing jejunoileal bypass surgery, which is likely to increase portal endotoxemia, are more prone to developing steatohepatitis. By facilitating neutrophil chemotaxis, these cytokines promote an inflammatory response that results in cellular degeneration and progression of NASH. Animal models have shown that obesity increases sensitivity to endotoxinmediated liver damage 24 Insulin resistance and hyperinsulinemia have been shown to be associated with nonalcoholic fatty liver disease. 25 A recent study found that insulin resistance and hyperinsulinemia are associated with fatty liver, regardless of BMI or fat distribution, suggesting that insulin resistance may be the primary phenomenon, with obesity and splanchnic fat distribution being the effects of insulin resistance rather than being directly involved in the pathogenesis of hepatic steatosis. 25 Additionally, investigators have shown that postprandial serum insulin levels are higher in patients with NASH. 26 Resistance to peripheral action of insulin (characteristic of type 2 diabetes) facilitates lipolysis, resulting in increased production of free fatty acids. These free fatty acids, apart from serving as substrates for triglyceride synthesis and thus leading to steatosis, may directly increase cellular oxidative stress via peroxisomal ~-oxidation of free fatty acids and increasing expression of CYP 2E1.
ROLE OF HEPATIC IRON
The role of hepatic iron in the progression of NASH remains controversial, but in some patients, iron may have a role in the pathogenesis of NASH by promoting oxidative stress. Iron is a potent catalyst of oxidative stress and may act synergistically with other promoters of lipid peroxidation by catalyzing these reactions. Thon overload can also directly cause lipid peroxidation, and one of the subsequent products, malondialdehyde, has been shown to activate hepatic stellate cells in vitro, the maj6r source of fibrogenesis in liver injury. 27 George et al 28 reported a higher prevalence of the Cys282Tyr mutation of the HEE gene in patients with NASH, although there was no difference in the frequency of the His63Asp mutation. The presence of the Cys282Tyr mutation was associated with increased hepatic iron staining and hepatic iron concentration, and the increased hepatic iron correlated with the severity of fibrosis. Bonkovsky et al 29 also reported a significantly higher prevalence of heterozygosity for either mutation in patients with NASH.
The effect of heterozygosity for the HFE gene on hepatic fibrosis is not specific for NASH, and its importance is still uncertain. Patients with chronic hepatitis C virus who are heterozygous for the HFE gene have more fibrosis on biopsy specimens, an effect independent of hepatitis C virus RNA levels or degree of inflammation. 30 In a recent series, Younossi et al found no significant iron accumulation in patients. with nonalcoholic fatty liver and no association between hepatic iron and aggressive histological or clinical outcome. Additionally, another recent report' 3 found no association between increased transferrin saturation and degree of fibrosis in NASH.
SYMPTOMS, SIGNS, AND LABORATORY STUDIES
Most patients with NASH are asymptomatic, although some may have fatigue, malaise, or right upper quadrant discomfort. Often the only clinical sign is hepatomegaly, which may not be present in all patients. Few patients have cutaneous signs of chronic liver disease, but the presence of ascites, splenomegaly, spider angiomas, and palmar erythema suggests underlying cirrhosis with portal hypertension. Laboratory studies for NASH are non-diagnostic but essential for excluding other potential causes of liver disease. There are no reliable distinguishing laboratory features of NASH vs simple fatty liver or NASH vs alcoholic steatohepatitis. Generally, modest elevations of aminotransferase levels are noted (in the 2-to 3-fold range), and unlike alcoholic hepatitis, elevation of alanine aminotransferase (ALT) levels may exceed that of aspartate aminotransferase (AST) levels. Of note, a recent study identified an AST/ALT ratio greater than 1 as an independent predictor of liver fibrosis in patients with NASH. 13 However, some patients with NASH may have normal aminotransferase levels. Less than one half of patients have an elevated alkaline phosphatase level, which is almost always modest, and only 10% to 15% have elevated serum conjugated bilirubin levels. The serum albumin level and prothrombin time are typically normal in the absence of cirrhosis.
EVALUATION OF A PATIENT WITH SUSPECTED NASH
As with other liver diseases, the diagnostic evaluation of suspected NASH begins with a history and physical examination of the patient, with attention to factors like alcohol consumption, medications, and concurrent systemic disorders. NASH can be diagnosed only after excessive alcohol consumption has been excluded, although the threshold for defining excessive alcohol consumption is uncertain. As previously mentioned, the laboratory features of NASH are non-diagnostic. A reasonable evaluation to exclude other potentially treatable causes of liver disease must be performed and may include serologic testing for hepatitis C and B, serum iron studies, testing for presence of antinuclear antibodies as well as anti-smooth muscle and anti-mitochondrial antibodies, and determination of serum ceruloplasmin and α 1 -antitrypsin levels. If drug-induced liver injury is suspected, a trial of drug withdrawal may be warranted. If the alkaline phosphatase level is elevated (which is not typical in NASH), imaging of the liver and biliary tree should be performed to rule out biliary obstruction. Imaging modalities such as ultrasonography, computed tomography, or magnetic resonance imaging may suggest the presence of hepatic steatosis but do not reliably distinguish between simple fatty liver and NASH. Ultrasonography generally shows a diffusely echogenic liver. When imaging modalities suggest steatosis in the presence of elevated aminotransferase levels with no other known causes of fatty liver, liver biopsy may be indicated to confirm the diagnosis. Liver biopsy remains the gold standard for diagnosing NASH, -and the diagnosis is suggested by typical pathologic findings. However, because of the generally indolent nature of the disease and the lack of proven treatment, many clinicians do not recommend liver biopsy.
CLINICAL COURSE AND NATURAL HISTORY
Although simple fatty liver is probably not progressive, patients with NASH can develop progressive fibrosis. Prospective studies of the natural history of NASH are lacking. The major series reporting follow-up with liver histological studies have each been retrospective, with a total of only 28 patients undergoing serial liver biopsies over a 1-to 7-year period. 8 -10 Among these 28 patients, 1 experienced improvement, no change was evident in 15, and 12 (43%) had histological progression, 4 of whom developed cirrhosis. Therefore, the available data suggest that, although NASH generally has an indolent clinical course, a substantial proportion of patients may develop progressive fibrosis that leads to cirrhosis and subsequent complications from portal hypertension. 8 -10 As yet, no clinical, laboratory, or histological findings have been noted that might identify the subset of patients at risk of progression, except perhaps for those with fibrosis on the initial biopsy specimen. In a recent series, older age, obesity, diabetes mellitus, and an AST/ALT ratio greater than 1 were found to be independent predictors of liver fibrosis in NASH. 13 This may help identify the subset of patients at risk of progression, and thus more aggressive therapy can be attempted. An increased risk of fibrosis has been reported in Patients with NASH who have mildly increased hepatic iron stores. 28 Some evidence shows that NASH may evolve into inactive non-fatty cirrhosis after several years, and this condition may have been termed "cryptogenic" if an index biopsy had not been performed. In a recent series, many patients with cryptogenic cirrhosis had characteristics similar to those in patients with NASH. 32 Thus, NASH is probably an under-recognized cause of cirrhosis. The absence of steatosis and inflammation as NASH progresses has been observed sporadically and needs further study.
The incidence of hepatocellular carcinoma in NASH is completely unknown, although sporadic cases have been reported.
TREATMENT
Currently, no available therapy is known to alter the course of NASH. A single treatment option may be infeasible because of the probable multiple mechanisms involved and perhaps different predominant mechanisms in various patients (such as lean vs obese patients). If NASH-is diagnosed, the degree of fibrosis present, if any, could be of importance in tailoring the aggressiveness of therapy. Because no absolute correlation exists between serum test 
CLINICAL COURSE AND NATURAL HISTORY
Although simple fatty liver is probably not progressive, patients with NASH can develop progressive fibrosis. Prospective studies of the natural history of NASH are lacking. The major series reporting follow-up with liver histological studies have each been retrospective, with a total of only 28 patients undergoing serial liver biopsies over a 1-to 7-year period. 8 -10 Among these 28 patients, 1 experienced improvement, no change was evident in 15, and 12 (43%) had histological progression, 4 of whom developed cirrhosis. Therefore, the available data suggest that, although NASH generally has an indolent clinical course, a substantial proportion of patients may develop progressive fibrosis that leads to cirrhosis and subsequent complications from portal hypertension. 8 
-'
0 As yet, no clinical, laboratory, or histological findings have been noted that might identify the subset of patients at risk of progression, except perhaps for those with fibrosis on the initial biopsy specimen. In a recent series, older age, obesity, diabetes mellitus, and an AST/ALT ratio greater than 1 were found to be independent predictors of liver fibrosis in NASH. ' 3 This may help identify the subset of patients at risk of progression, and thus more aggressive therapy can be attempted. An increased risk of fibrosis has been reported in Patients with NASH who have mildly increased hepatic iron stores. 28 Some evidence shows that NASH may evolve into inactive non-fatty cirrhosis after several years, and this condition may have been termed "cryptogenic" if an index biopsy had not been performed. In a recent series, many patients with cryptogenic cirrhosis had characteristics similar to those in patients with NASH. 32 Thus, NASH is probably an under-recognized cause of cirrhosis. The absence of Steatosis and inflammation as NASH progresses has been observed sporadically and needs further study.
TREATMENT
Currently, no available therapy is known to alter the course of NASH. A single treatment option may be infeasible because of the probable multiple mechanisms involved and perhaps different predominant mechanisms in various patients (such as lean vs obese patients). If NASH is diagnosed, the degree of fibrosis present, if any, could be of importance in tailoring the aggressiveness of therapy. Because no absolute correlation exists between serum test results and disease activity, liver biopsy is the only true measure of treatment efficacy. As most patients with NASH are obese, weight loss is commonly recommended, although weight reduction has not been studied systematically and prospectively. Modest gradual, sustained weight loss has been shown to result in improvement of serum aminotransferase levels and in liver histology. 14. 33 Since many of the presumed pathophysiologic mechanisms involved in alcoholic and nonalcoholic steatohepatitis are similar, a reasonable strategy may be to restrict all alcohol intake in patients with NASH, especially in those with fibrosis on a biopsy specimen. However, the effect of small amounts of alcohol intake on the progression of NASH~ remains unknown.
When diabetes coexists with NASH, treatment of the diabetes is a standard recommendation, although no evidence shows that control of diabetes affects the activity or progression of NASH. Nonetheless, good glycemic control in such patients seems reasonable.
Similar to treatment of diabetes, therapy for any hyperlipidemia present in NASH has not been shown to decrease disease activity, but this approach seems to be reasonable. In a pilot study, no significant clinical, biochemical, or histological improvement was noted after 1 year of therapy with clofibrate.
11 However, preliminary results suggest possible benefit with gemfibrozil; significant improvement in mean ALT and AST levels was noted after 4 weeks of therapy with gemfibrozil. There have been no reported clinical trials of use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in patients with NASH.
In a pilot study of ursodeoxycholic acid (UDCA) in the treatment of NASH, significant improvement in levels of ALT, alkaline phosphatase, and γ-glutamyl transpeptidase and grade of hepatic steatosis was noted in most patients after 1 year of therapy, suggesting a possible role for UDCA in the treatment of NASH." However, there was no significant change in the histological grade of inflammation or fibrosis. Although the precise mechanism of action of UDCA is unclear, its cytoprotective action is thought to have a role. Randomized controlled trials are under way to confirm the possible beneficial effect of UDCA in NASH.
Because an increase in hepatic iron has been found to correlate with severity of fibrosis, 28 phlebotomy to remove excess iron may potentially have a beneficial effect in preventing the progression of fibrosis. Desai and Chiorean 35 reported significant improvement in mean ALT levels after phlebotomy in 8 patients, all of who had 1+ or lower iron staining on biopsy. However, the effect of phlebotomy on liver histology in NASH must be evaluated further.
NASH AND LIVER TRANSPLANTATION
Cirrhosis due to NASH may eventuate in liver transplantation. Orthotopic liver transplantation (OLT) is an alternative for patients with end-stage liver disease due to cirrhosis and complications of portal hypertension. However, NASH can recur after OLT, especially in patients who had previously undergone jejunoileal bypass surgery.
3~ Kim et al 37 reported recurrent steatosis in 6 of 8 patients who underwent transplantation because of NASH, 3 of whom had evidence of recurrent NASH. In 5 of the 6 patients, fatty infiltration occurred within 4 months of OLT. Another report found that, of 5 patients with NASH who underwent transplantation not associated with gastrointestinal bypass surgery, NASH recurred in 2 patients at 4 and 6 weeks posttransplantation. One of these patients required re-transplantation, and NASH recurred again at 3 weeks. 38 These cases support the concept that a systemic derangement of fat metabolism that is not "cured" by liver transplantation is responsible for NASH.
CONCLUSION
NASH is a metabolic disease that is probably caused by multifaceted disturbances of hepatic lipid homeostasis, the prevalence of which is higher than previously thought. It should be considered in the differential diagnosis of asymptomatic patients with persistently elevated liver enzymes, particularly in the presence of other risk factors (obesity, diabetes, hyperlipidemia). However, it should also be considered in lean, otherwise healthy patients with elevated aminotransferase levels. Liver biopsy is essential to confirm the diagnosis of NASH, and findings vary from mild steatohepatitis to severe fibrosis and cirrhosis. The course of NASH is highly variable but is probably underestimated as a cause of cirrhosis. Although no proven therapy exists, gradual sustained weight loss and UDCA may have a beneficial effect. NASH may recur after liver transplantation if the underlying pathophysiologic disturbances are not addressed.
